Summary
Eli Lilly and Company (LLY) announced on December 11, 2011, the election of Katherine Baicker to its Board of Directors, effective December 12, 2011. Ms. Baicker's appointment brings a strong background in health economics and policy to the board, with experience including a prior role on the President's Council of Economic Advisers and extensive academic and advisory positions in health-related fields. This strategic addition to the board, particularly her role on the public policy and compliance committee, suggests a continued focus by Eli Lilly on navigating the complex landscape of healthcare policy and regulation. Investors can view this as a positive development, indicating the company's commitment to informed decision-making in an area critical to its pharmaceutical business. Ms. Baicker will serve under interim election until shareholders vote on her permanent placement at the company's annual meeting in April 2012.
Key Highlights
- 1Eli Lilly's Board of Directors appointed Katherine Baicker as a new member.
- 2The appointment is effective December 12, 2011.
- 3Katherine Baicker is a Professor of Health Economics at Harvard School of Public Health.
- 4She has prior experience as a Member of the President's Council of Economic Advisers (2005-2007).
- 5Ms. Baicker will serve on the board's public policy and compliance committee.
- 6Her appointment is subject to shareholder approval at the April 2012 annual meeting.
- 7This addition brings significant expertise in health policy and economics to the board.